Edition:
United Kingdom

People: Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.18USD
22 Jun 2018
Change (% chg)

$-0.01 (-0.31%)
Prev Close
$3.19
Open
$3.26
Day's High
$3.28
Day's Low
$3.02
Volume
3,319,279
Avg. Vol
728,928
52-wk High
$4.71
52-wk Low
$2.15

Lapointe, Gregg 

Mr. Gregg Lapointe, CPA, MBA., serves as Director of the Company. Currently the chief executive officer (CEO) and co-founder of Cerium Pharmaceuticals, Inc., Mr. Lapointe offers Rigel's board nearly three decades of commercial and financial experience bringing products to market in the areas of medical devices and rare diseases. A certified public accountant and graduate of theDuke UniversityFuqua School of Business, Mr. Lapointe began his career in accounting as well as mergers and acquisition inMontreal, Canadabefore moving into a leadership role at Ingram & Bell Meditron and Medical Plastic Devices MPD Inc. In 2001, Mr. Lapointe joined Sigma-Tau Pharmaceuticals, Inc. where he rose from vice president of finance to chief executive officer, overseeing a company focused exclusively on the development and commercialization of medicines for rare diseases. During his tenure, the company grew to nine marketed products in the rare disease space (small molecule, biologics, medical foods) with an extensive clinical development pipeline. In 2012, Mr. Lapointe founded and became the CEO of Cerium Pharmaceuticals, Inc., a start-up focused on developing and commercializing medicines for patients with rare diseases. Presently, Mr. Lapointe also sits on the board of Soligenix, Inc. and Cytori Therapeutics, Inc. He previously sat on the board of SciClone Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Raptor Pharmaceuticals, Inc., Questcor Pharmaceuticals, Inc. and Cambrooke Therapeutics, Inc., among others. From 2009 to 2012, Mr. Lapointe was a member of the Board of Directors, and Chair of the Rare Disease Committee, of the Pharmaceutical Research and Manufacturers of America (PhRMA) inWashington, DC.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --